Arjun, S;
Bell, RM;
(2019)
SGLT2 inhibitors: reviving the sodium-hydrogen exchanger cardioprotection hypothesis?
[Editorial comment].
Cardiovascular Research
, 115
(10)
pp. 1454-1456.
10.1093/cvr/cvz105.
Preview |
Text
Bell_SGLT2 inhibitors - the NHE hypothesis -editorial.pdf - Accepted Version Download (480kB) | Preview |
Abstract
This editorial refers to ‘Delayed ischemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts’, by L. Uthman et al., doi:10.1093/cvr/cvz004. The sodium-glucose linked transporter-2 (SGLT2) inhibitors, targeted to improve glycaemic control by attenuating renal glucose re-uptake, are emerging to be one of the most impactful cardiovascular drug classes of recent times. With clear and rapid-onset benefit upon cardiovascular outcomes, particularly in respect to heart failure rehospitalization,1 SGLT2 inhibitors are rapidly becoming an essential part of the Cardiologist’s pharmacopoeia. Remarkably, the mechanisms belying the cardioprotective effects of SGLT2 inhibitors remain obscure. Understanding the mechanisms behind their benefits is not a purely academic exercise: identifying how they influence the cardiovascular system will not only improve our understanding of the pathophysiology of cardiovascular disease, but also potentially enable re-purposing of these drugs beyond their current indications in patients with Type 2 diabetes mellitus.
Archive Staff Only
 |
View Item |
